AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Oncology Powerhouse | AstraZeneca's robust oncology portfolio and pipeline drive growth, with key drugs like Enhertu and Imfinzi showing promising results in various cancer treatments |
Financial Strength | Raised guidance for 2024 reflects confidence, with total revenue and core earnings expected to grow in mid-teens percentage at constant exchange rates |
Strategic Expansion | Explore AstraZeneca's moves into earlier treatment lines and new therapeutic modalities, including antibody-drug conjugates and CAR-T cell therapies |
Market Valuation | Analysts set price targets ranging from $82 to $89, with AstraZeneca appearing undervalued based on InvestingPro's Fair Value analysis |
Metrics to compare | AZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZNPeersSector | |
---|---|---|---|---|
P/E Ratio | 34.2x | 23.4x | −0.5x | |
PEG Ratio | 1.87 | 0.06 | 0.00 | |
Price/Book | 5.9x | 3.1x | 2.6x | |
Price / LTM Sales | 4.4x | 2.5x | 3.0x | |
Upside (Analyst Target) | 13.2% | 39.7% | 56.3% | |
Fair Value Upside | Unlock | 31.1% | 10.0% | Unlock |